Key pointsMonash researchers have uncovered the hidden 'code' governing how genetic mutations affect RNA splicing and result in diseaseBreakthrough ...
The LineaIVT platform is an integrated system that combines the Company’s LineaDNA and LineaRNAP technologies, the latter a next-generation RNAP engineered with a patented DNA-binding domain that ...
In the fast-evolving field of medical science, a new artificial intelligence model may be about to change the way mRNA-based drugs and vaccines are designed. Developed through a collaboration between ...
Clay Shorrock, executive director of business development with LineaRx, an Applied DNA Sciences company, stated, "Therapy developers and CDMOs in our Linea IVT sales pipeline unanimously cite dsRNA ...
Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he's pulling the plug on nearly $500 million in funding for the development of mRNA vaccines. Here's how they work.
Nucleic acid-based therapeutics, including antisense oligonucleotides (ASO), small interfering RNA (siRNA), messenger RNA (mRNA), immunomodulatory DNA/RNA, and gene-editing guide RNA (gRNA), hold ...
Recently, demands in RNA manufacturing for long-chain RNAs exceeding 100 nucleotides, such as single guide RNA (sgRNA) for genome editing, have been increasing. Generally, these types of RNA are ...
With support from the National Institutes of Health, the COBRE Center for RNA Biology in Health and Disease will create a ...
Vaccines using mRNA technology weren’t immune to the latest round of federal research cuts. Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he’s pulling the plug on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback